Shopping Cart
Remove All
Your shopping cart is currently empty
BGP-15 (BGP-15 2HCl) is a PARP inhibitor with protecting effect after ischemia-reperfusion injury.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $29 | In Stock | In Stock | |
| 10 mg | $47 | In Stock | In Stock | |
| 25 mg | $95 | In Stock | In Stock | |
| 50 mg | $158 | In Stock | In Stock | |
| 100 mg | $257 | In Stock | In Stock | |
| 200 mg | $378 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $32 | In Stock | In Stock |
| Description | BGP-15 (BGP-15 2HCl) is a PARP inhibitor with protecting effect after ischemia-reperfusion injury. |
| Targets&IC50 | PARP:120 μM |
| In vitro | In two mouse models developed to exhibit heart failure and atrial fibrillation, BGP-15 has been shown to enhance cardiac function and reduce arrhythmia [2]. Pretreatment with BGP-15 (100-200 mg/kg, p.o.) before cisplatin administration can either prevent or significantly inhibit the development of cisplatin-induced acute renal failure. BGP-15 demonstrates significant antioxidant effects on the kidneys in the context of cisplatin-induced nephrotoxicity. Despite BGP-15's ability to protect the kidneys from nephrotoxic effects, it does not diminish the antitumor efficacy of cytostatic agents. In the kidneys, BGP-15 inhibits cisplatin-induced poly(ADP-ribose) polymerization [1]. |
| In vivo | BGP-15 acts as an in vitro inducer of HSP72, effective only when co-treated with heat shock, without affecting HSP90 levels. At a concentration of 200 μM, BGP-15 mitigates the depletion of high-energy phosphate compounds and prevents oxidative damage induced by imatinib mesylate. This is achieved by promoting the phosphorylation of Akt and GSK-3beta, and inhibiting the activation of p38 MAPK and JNK, thereby altering the signaling effects of imatinib mesylate. Moreover, BGP-15 significantly inhibits the activation of p38 and JNK, enzymes known to facilitate cell death and inflammatory responses in ex vivo perfused hearts. |
| Cell Research | Human tumor cell lines A549, HCT-15, HCT-116, and Du-145 were maintained in RPMI 1640 medium supplemented with 10% FCS in humidified air containing 5% CO2. For in vitro cytotoxicity assays, 5×103 to 5×104 cells were plated into the wells of 96-well plates in 100 μL culture medium. On the following day, cells were exposed to BGP-15 (10, 30, 100 μg/mL) and to a series of concentrations of cisplatin either by itself or in combination. Cultures were incubated in a total volume of 200 μL for 3 more days at 37°. Samples were prepared in duplicates or triplicates. Cell growth was evaluated by MTT or SRB assays. Growth inhibition curves were calculated. (Only for Reference) |
| Synonyms | BGP15 2hydrobromide, BGP-15 2HCl |
| Molecular Weight | 351.27 |
| Formula | C14H24Cl2N4O2 |
| Cas No. | 66611-37-8 |
| Smiles | Cl.Cl.N\C(=N/OCC(O)CN1CCCCC1)c1cccnc1 |
| Relative Density. | no data available |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 64 mg/mL (182.2 mM), Sonication is recommended. Ethanol: 65 mg/mL (185.04 mM), Sonication is recommended. DMSO: 65 mg/mL (185.04 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.69 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/Ethanol/DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.